MGI PHARMA to Present at the 2005 Banc of America Securities Health Care Conference
10 Mayo 2005 - 6:00AM
Business Wire
MGI PHARMA, INC. (Nasdaq:MOGN), an oncology-focused
biopharmaceutical company, today announced that it will present at
the 2005 Banc of America Securities Health Care Conference on
Tuesday, May 17 at 5:40 p.m. Eastern Time. Jim Hawley, senior vice
president and chief financial officer of MGI PHARMA, will give the
presentation, which will be webcast live over the Internet. The
conference will be held at the Four Seasons Hotel in Las Vegas, NV.
-0- *T What: MGI PHARMA's presentation at the 2005 Banc of America
Securities Health Care Conference When: Tuesday, May 17, 2005 at
5:40 p.m. Eastern Time How: Live over the Internet - simply log on
to www.mgipharma.com. In addition to the live webcast, the
presentation will be archived on the Company's website for one
month. *T About MGI PHARMA MGI PHARMA, INC. is an oncology-focused
biopharmaceutical company that acquires, develops and
commercializes proprietary products that address the unmet needs of
cancer patients. MGI PHARMA has a portfolio of proprietary
pharmaceuticals, and intends to become a leader in oncology. MGI
PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection,
Kadian(R) (sustained release morphine sulfate capsules), Salagen(R)
Tablets (pilocarpine hydrochloride) and Hexalen(R) (altretamine)
capsules in the United States. The Company directly markets its
products in the U.S. and collaborates with partners to reach
international markets. For more information about MGI PHARMA,
please visit www.mgipharma.com. This news release contains certain
"forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are
typically preceded by words such as "believes," " expects,"
"anticipates," "intends," "will," "may," "should," or similar
expressions. These forward-looking statements are not guarantees of
MGI PHARMA's future performance and involve a number of risks and
uncertainties that may cause actual results to differ materially
from the results discussed in these statements. Factors that might
cause the Company's results to differ materially from those
expressed or implied by such forward-looking statements include,
but are not limited to, the ability of MGI PHARMA's product
candidates to be proven safe and effective in humans, to receive
marketing authorization from regulatory authorities, and to
ultimately compete successfully with other therapies; continued
sales of MGI PHARMA's marketed products; development or acquisition
of additional products; reliance on contract manufacturing; changes
in strategic alliances; continued access to capital; and other
risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission including its
most recently filed Form 10-Q or 10-K. MGI PHARMA undertakes no
duty to update any of these forward-looking statements to conform
them to actual results.
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Mgi Pharma (MM) (NASDAQ): 0 recent articles
Más de MGI PHARMA, INC. Artículos de Noticias